Clinical trial
An Open-label, Phase 1b Multicenter Study of IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
NCT03568539 is registered in ClinicalTrials.gov with Innovent Biologics (Suzhou) Co. Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Phase 1b Multicenter Study of IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 27, 2018
- Completion date
- December 7, 2020
- Enrollment
- 39 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
advanced/metastatic solid malignancies